Home > Oncology > SABCS 2019 > Triple-Negative Breast Cancer > No higher pathologic complete response with atezolizumab added to chemotherapy

No higher pathologic complete response with atezolizumab added to chemotherapy

Conference
SABCS 2019
Trial
IMpassion130

Adding atezolizumab to nab-paclitaxel and carboplatin did not significantly increase the rate of pathologic complete response in women with triple-negative breast cancer. However, in multivariate analyses, the presence of programmed death-ligand 1 (PD-L1) expression was the most significant factor influencing the rate of pathological complete response.

Triple-negative breast cancer of high proliferation or grade is a subgroup characterised by very poor prognosis, rapid progression to metastatic stage, and rapid onset of resistance to chemotherapy after initial response. As a whole, triple-negative breast cancer represents a specific area of medical need, in which new therapeutic approaches need to be thoroughly evaluated to provide new options for this specific patient population. Immune infiltration of triple-negative breast cancer is linked to prognosis and probability of response to chemotherapy. Blockade of PD-L1 or programmed cell death protein 1 (PD-...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on